课题基金 / 基金详情

Innovation in Medical Evidence Development and Surveillance(IMEDS)serves to advance the science and tools necessary to support post-market evidence generation on regulated products.

Innovation in Medical Evidence Development and Surveillance(IMEDS)serves to advance the science and tools necessary to support post-market evidence generation on regulated products.
医学证据开发和监测创新 (IMEDS) 致力于推进支持受监管产品上市后证据生成所需的科学和工具。
批准号:
9074987
负责人:
Susan Gruber
金额:
$100.0万
依托单位国家:
美国
项目类别:
财政年份:
2015
资助国家:
美国
项目状态:
已结题
起止时间:
2015-07-20 至 2016-07-21

项目摘要

项目成果

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
Opportunity Title: IMEDS-Methods Research Agenda Offering Agency: Food and Drug Administration CFDA Number: 93.103 CFDA Description: Food and Drug Administration_Research Opportunity Number: RFA-FD-15-010 PI Name: Susan Gruber Project Title: IMEDS-Methods Research Agenda Abstract: IMEDS-Methods is a program within the Reagan-Udall Foundation (RUF) that supports the FDA’s scientific mission of serving public health needs by initiating and facilitating research into the methods of safety evaluation in large databases. IMEDS-Methods aims to improve the tools for conducting post- marketing safety surveillance using automated healthcare data and to foster their adoption. In meeting this mission, IMEDS-Methods also adds to the general body of knowledge for using automated health data for broader post-market evidence generation on regulated products.1 The overarching goal of the IMEDS-Methods Program is to reduce uncertainty in the FDA’s ongoing evaluation of marketed medical products. Projects on the IMEDS-Methods 2015 Research Agenda are geared towards improving our ability to use electronic healthcare data to inform regulatory decision- making. IMEDS plans to fund projects in five core areas: (1) addressing bias in estimates from observational studies; (2) better understanding uses and limitations of the data; (3) applying lessons learned from earlier IMEDS projects to FDA surveillance activities; (4) expanding the surveillance question to continuous Risk/Benefit assessment; and (5) continuing to support qualified investigators in industry, government, and academic settings by providing access to de-identified electronic healthcare data and computing resources through the IMEDS Research Laboratory. Enhancements to the IMEDS Research Lab include developing novel tools and additional data sources to investigators in the research community. 1 Innovation in Medical Evidence Development and Surveillance (IMEDS) Charter. http://www.reaganudall.org/our-work/safety- and%20better-evidence/imeds-program/imeds-charter/ accessed September 30, 2013. First Draft Completed: April 2013 Proposed Revised Draft: August 2013; Section 3.1
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
国内基金
海外基金
Data-driven Recommendation System Construction of an Online Medical Platform Based on the Fusion of Information